The US Food and Drug Administration (FDA) has approved Grifols’ first immunoglobulin Xembify®, 20% solution for the treatment of primary immunodeficiencies in patients as young as 2 years old.
https://blog.genexi.ru/news/FDA-Approves-Xembify-for-Primary-Immunodeficiencies-en
